[Pharmacokinetic and clinical studies on aztreonam in neonates].
Pharmacokinetic and clinical studies on aztreonam (AZT) in mature and premature neonates were carried out. The results are summarized as follows. The mean serum peak level of AZT after intravenous administration at a single dose of 20 mg/kg in 3 to 4 day-old-neonates was 36.6 +/- 2.39 micrograms/ml at 1 hour after dosage. The mean serum level at 6 hours after dosage was 13.5 +/- 2.03 micrograms/ml. The mean half-life time was 3.86 +/- 0.92 hours. The mean urinary excretion rate was 25.1 +/- 5.18% in the first 6 hours after intravenous administration. AZT was administered in 4 cases, but the effects could not be evaluated. No side effect was observed except an elevation of GOT.
Nishimura
T
T
Department of Pediatrics, Osaka Medical College.
Tabuki
K
K
D000667:Ampicillin / Q000008:administration & dosage; D001398:Aztreonam / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000517:prevention & control; D004359:Drug Therapy, Combination; D005260:Female; D006207:Half-Life; D006801:Humans; D007231:Infant, Newborn; D008297:Male
D000667:Ampicillin; D001398:Aztreonam